Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Carnival Stock Today (November 22, 2025): Price, Institutional Buying, Loyalty Revamp and FBI Probe

Carnival Stock Today (November 22, 2025): Price, Institutional Buying, Loyalty Revamp and FBI Probe

Carnival Corporation & plc heads into the weekend with its share price back on the front foot, a wave of fresh institutional buying, a controversial overhaul of its loyalty program pushed back after customer backlash, and intense media scrutiny over an FBI investigation into a passenger death on one of its ships. Together, these threads are shaping how investors are looking at Carnival stock today.
22 November 2025
··
Alphabet (GOOG) Stock Today: Buffett’s $4.3 Billion Bet, Gemini 3 “Hit” and a New $3.6 Trillion Milestone (Nov. 22, 2025)

Alphabet (GOOG) Stock Today: Buffett’s $4.3 Billion Bet, Gemini 3 “Hit” and a New $3.6 Trillion Milestone (Nov. 22, 2025)

Alphabet heads into the weekend sitting near all‑time highs after a frenetic stretch of AI announcements, massive infrastructure spending plans, and a rare endorsement from Warren Buffett’s Berkshire Hathaway. As of Friday’s close, Alphabet’s Class C shares finished around $299.65, up roughly 3.3% on the day, with after‑hours trading on Saturday showing prices edging above $302. Yahoo Finance+2StockAnalysis+2
22 November 2025
··
1 … 605 606 607

Stock Market Today

  • Alignment Healthcare (ALHC) Soars 238% in Three Years Despite Ongoing Legal Challenges
    July 25, 2026, 8:05 PM EDT. Alignment Healthcare (ALHC) has jumped 237.9% over three years and returned 65.2% in the last year. The shares remain under pressure from legal issues involving whistleblower claims, yet trade at a price-to-sales ratio of 0.9x, undercutting the Healthcare sector's 1.4x average. Strong value metrics suggest the stock could be undervalued when compared to its sales and industry peers.